TCM
TEVA icon

Tekla Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Tekla Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$3.46M Hold
459,651
– – 0.14% 95
2023
Q1 		$4.07M Hold
459,651
– – 0.15% 86
2022
Q4 		$4.19M Hold
459,651
– – 0.16% 83
2022
Q3 		$3.71M Hold
459,651
– – 0.15% 91
2022
Q2 		$3.46M Hold
459,651
– – 0.14% 97
2022
Q1 		$4.32M Hold
459,651
– – 0.15% 100
2021
Q4 		$3.68M Sell
459,651
-148,000
-24% -$1.34M 0.12% 112
2021
Q3 		$5.92M Hold
607,651
– – 0.19% 97
2021
Q2 		$6.02M Sell
607,651
-52,900
-8% -$560K 0.2% 110
2021
Q1 		$7.62M Sell
660,551
-69,500
-10% -$797K 0.26% 96
2020
Q4 		$7.04M Sell
730,051
-55,800
-7% -$535K 0.25% 101
2020
Q3 		$7.08M Hold
785,851
– – 0.27% 85
2020
Q2 		$9.69M Hold
785,851
– – 0.37% 57
2020
Q1 		$7.06M Hold
785,851
– – 0.32% 63
2019
Q4 		$7.7M Hold
785,851
– – 0.29% 78
2019
Q3 		$5.41M Hold
785,851
– – 0.24% 77
2019
Q2 		$7.25M Sell
785,851
-105,138
-12% -$1.27M 0.3% 74
2019
Q1 		$14M Sell
890,989
-320,879
-26% -$5.66M 0.57% 42
2018
Q4 		$18.7M Buy
1,211,868
+278,920
+30% +$5.72M 0.8% 32
2018
Q3 		$20.1M Sell
932,948
-150,895
-14% -$3.5M 0.73% 36
2018
Q2 		$26.4M Buy
1,083,843
+620
+0.1% +$12.6K 1% 27
2018
Q1 		$18.5M Sell
1,083,223
-499,885
-32% -$9.76M 0.72% 33
2017
Q4 		$30M Sell
1,583,108
-173,450
-10% -$2.61M 1.16% 24
2017
Q3 		$30.9M Buy
1,756,558
+740,800
+73% +$16.7M 1.11% 25
2017
Q2 		$33.7M Hold
1,015,758
– – 1.25% 21
2017
Q1 		$32.6M Buy
1,015,758
+226,800
+29% +$7.74M 1.26% 23
2016
Q4 		$28.6M Hold
788,958
– – 1.22% 24
2016
Q3 		$36.3M Buy
788,958
+117,000
+17% +$6.1M 1.4% 23
2016
Q2 		$33.8M Hold
671,958
– – 1.38% 21
2016
Q1 		$36M Sell
671,958
-662,279
-50% -$38.9M 1.53% 17
2015
Q4 		$87.6M Sell
1,334,237
-51,357
-4% -$3.17M 3.18% 9
2015
Q3 		$78.2M Sell
1,385,594
-2,000
-0.1% -$130K 2.81% 10
2015
Q2 		$82M Buy
1,387,594
+390,000
+39% +$24.1M 2.97% 11
2015
Q1 		$62.1M Buy
997,594
+574,000
+136% +$33.4M 2.46% 10
2014
Q4 		$24.4M Sell
423,594
-228,600
-35% -$12.7M 1.14% 22
2014
Q3 		$35.1M Buy
652,194
+340,718
+109% +$18.1M 1.64% 15
2014
Q2 		$16.3M Hold
311,476
– – 1.5% 19
2014
Q1 		$16.5M Hold
311,476
– – 1.65% 19
2013
Q4 		$12.5M Sell
311,476
-43,000
-12% -$1.69M 1.31% 21
2013
Q3 		$13.4M Buy
354,476
+43,000
+14% +$1.68M 1.49% 21
2013
Q2 		$12.2M Buy
+311,476
New +$12.1M 1.66% 19

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tekla Capital Management's TEVA Position: Q2 2023 in Review

Tekla Capital Management held its Teva Pharmaceuticals (TEVA) position steady in Q2 2023 at 459,651 shares worth $3.46M. The position accounts for 0.14% of the portfolio, ranked #95.

Tekla Capital Management first reported a position in TEVA in Q2 2013 and has held it in 41 quarters since. The position peaked at $87.6M in Q4 2015. 428 funds tracked by Wall St. Rank hold TEVA as of Q2 2023.

  • Tekla Capital Management held 459,651 shares of Teva Pharmaceuticals worth $3.46M as of Q2 2023.
  • Tekla Capital Management left its Teva Pharmaceuticals share count unchanged in Q2 2023.
  • Teva Pharmaceuticals made up 0.14% of Tekla Capital Management's portfolio in Q2 2023, its #95 holding.
  • Tekla Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 41 quarters since.
  • Tekla Capital Management's Teva Pharmaceuticals position peaked at $87.6M in Q4 2015.
  • 428 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.